Primary Audience:

Oncologists and other health care professionals who treat and care for patients with breast cancer.

Learning Objectives

Upon completion of the activity, participants should be able to: 

1. Interpret results from new and existing HER2 testing methodologies to determine appropriate treatment decisions 
2. Differentiate between the prognostic and predictive implications associated with HER2 positivity 
3. Compare and contrast monoclonal antibodies and tyrosine kinase inhibitors available for the treatment of HER2-positive breast cancer 
4. Apply evidence-based clinical trial data on new and emerging treatment strategies to ensure optimal care for patients with HER2-positive breast cancer 
5. Monitor and manage treatment-related toxicities associated with chemotherapeutic and biologic agents used to treat HER2-positive breast cancer

Faculty:

Monica N. Fornier, MD 
Assistant Professor of Medicine 
Breast Cancer Medicine Service 
Memorial Sloan-Kettering Cancer Center 
New York, New York

BIO
Dr. Monica Fornier is an assistant member of the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center and specializes in the treatment of breast cancer. She is also an assistant professor at the Weill Cornell Medical College New York-Presbyterian Hospital. 

Dr. Fornier graduated summa cum laude from the University of Milan School of Medicine in Italy; she pursued her oncology fellowship at the National Cancer Institute of Milan, under the mentorship of Dr. Gianni Bonadonna, and a second fellowship at Memorial Sloan-Kettering Cancer Center in New York, under the mentorship of Dr. Larry Norton. She is currently a member of the faculty at Memorial Sloan-Kettering Cancer Center, where she conducts clinical research in breast cancer. 

Dr. Fornier is an active member of various national and international scientific groups, including the American Society of Clinical Oncology and the European Society of Medical Oncology. Dr. Fornier has numerous publications to her name and has presented data at several international meetings. 

Patrick G. Morris, MD, MSc
Special Fellow in Breast Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

BIO
Dr. Patrick Morris graduated summa cum laude from the University College Dublin Faculty of Medicine. In 2007, he was awarded a master of science degree at Trinity College Dublin. He pursued his oncology fellowship at the Royal College of Physicians of Ireland and in 2007 was awarded the Irish Society of Medical Oncology fellowship in advanced hematology and oncology at Memorial Sloan-Kettering Cancer Center. Since that time he has worked under the mentorship of Dr. Clifford Hudis. He has a special interest in the cardiac safety of anthracyclines and novel targeted therapies, including the development of biomarkers to predict toxicity. His other areas of research include the development of new therapies for metastatic breast cancer and the investigation of the pathways involved in metastases through collaborative translational research projects. 

Disclosure Summary:

education | outcomes | science is a CME provider accredited by the ACCME. In compliance with the Standards for Commercial Support, it is our policy to require everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest occurring within the 12 months prior to an activity's release date. The staff of education | outcomes | science involved with this activity have reported no relevant financial relationships with commercial interests. 

Activity Faculty 
Monica N. Fornier, MD has nothing to disclose. 
Patrick G. Morris, MD, MSc has received speaker's bureau honoraria from Genentech. 

Cleveland Clinic Foundation Activity Co-Chair 
G. Thomas Budd, MD, Professor of Medicine, The Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, discloses he has received honoraria for serving on an advisory board for Genentech.

Accreditation Statement/Designation of Credit:

education | outcomes | science is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

education | outcomes | science designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

To Obtain CME Credits:

1. Read the learning objectives and faculty disclosures. 
2. Participate in the activity. 
3. Complete the post-test and activity evaluation. 
4. Physicians who successfully complete the post-test and evaluation will receive CME credit. 
5. You must score 70% or higher on the post-test to receive credit for this activity. 
6. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Co-sponsored by:

education | outcomes | science and Cleveland Clinic.

The EOS privacy statement is available at http://eoscme.org/Privacy.aspx?section=ce

Copyright Information:

Copyright © 2009 education | outcomes | science. All rights reserved. 711 Third Avenue, 11th Floor | New York, NY 10017 | 212.849.7700 | info@eoscme.org

Hardware/Software Requirements and Technical Assistance: